Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.655 AUD 0.77% Market Closed
Market Cap: 225.9m AUD
Have any thoughts about
Aroa Biosurgery Ltd?
Write Note

EV/FCFF
Enterprise Value to FCFF

-15.8
Current
-17.2
Median
3.6
Industry
Higher than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-15.8
=
Enterprise Value
204.1m AUD
/
FCFF
-14.4m NZD
All Countries
Close
Market Cap EV/FCFF
NZ
Aroa Biosurgery Ltd
ASX:ARX
225.5m AUD -15.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -238 717.7
US
Abbvie Inc
NYSE:ABBV
312.7B USD 23.3
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 32.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD -80.1
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 10.7
US
Epizyme Inc
F:EPE
94.1B EUR -469.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 64.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 22.8
US
Seagen Inc
F:SGT
39.3B EUR -56.7
NL
argenx SE
XBRU:ARGX
34.5B EUR -101.2
 
NZ
Aroa Biosurgery Ltd
ASX:ARX
Average EV/FCFF: 30.7
Negative Multiple: -15.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -238 717.7
US
Abbvie Inc
NYSE:ABBV
23.3
US
Amgen Inc
NASDAQ:AMGN
32.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -80.1
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -469.9
AU
CSL Ltd
ASX:CSL
64.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -101.2

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More